Biotechnology company Clene Inc. announced significant progress in its neurological disease treatment research, with promising developments for patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
The company is preparing to submit a New Drug Application (NDA) under the FDA's Accelerated Approval pathway for ALS in the fourth quarter of 2025. Recent data demonstrated that their investigational therapy, CNM-Au8, substantially improved survival rates for patients with more advanced stages of ALS.
In addition to ALS research, Clene presented Phase 2 extension study results for MS, showing potential for remyelination and neuronal repair. The therapy targets mitochondrial function and the NAD pathway while reducing oxidative stress, offering a novel approach to treating neurodegenerative conditions.
Financially, Clene reported a first quarter net loss of $0.8 million, with $9.8 million in cash reserves sufficient to fund operations through the third quarter of 2025. The company's strategic focus on improving neurological treatments continues to drive its research and development efforts.
The potential FDA accelerated approval could represent a significant advancement in ALS treatment, offering hope for patients with limited therapeutic options. CNM-Au8's unique mechanism of action distinguishes it from current treatment approaches, potentially providing a breakthrough in managing this challenging neurodegenerative disease.
